GI 248573
Latest Information Update: 10 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Obesity therapies
- Mechanism of Action Cholecystokinin A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 15 Mar 1999 Discontinued-Clinical for Obesity in United Kingdom (Unknown route)
- 09 Jan 1998 Investigation in Obesity in United Kingdom (Unknown route)
- 14 Jul 1997 New profile